1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-111348A
    Lamifiban TFA
    Antagonist
    Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes.
    Lamifiban TFA
  • HY-136214
    R-BC154 acetate
    Antagonist
    R-BC154 acetate is a selective fluorescent α9β1 integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity.
    R-BC154 acetate
  • HY-P0295A
    Gly-Arg-Gly-Asp-Ser TFA
    Inhibitor
    Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ∼5 and ∼6.5 μM.
    Gly-Arg-Gly-Asp-Ser TFA
  • HY-P1702
    GR83895
    Inhibitor
    GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC50= 0.9 μM).
    GR83895
  • HY-B0686A
    Eptifibatide monoacetate
    Inhibitor
    Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
    Eptifibatide monoacetate
  • HY-14189
    Valategrast hydrochloride
    Antagonist
    Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.
    Valategrast hydrochloride
  • HY-P10667
    Ac-MRGDH-NH2
    Ac-MRGDH-NH2 is a pentapeptide containing the RGD sequence. Ac-MRGDH-NH2 can be used to synthesize the diastereoisomeric prodrugs Λ- and Δ-[Ru(Ph2phen)2(κS,κN-(Ac-MRGDH-NH2))]Cl2. In these prodrugs, Ac-MRGDH-NH2 serves as a photolabile protecting group for the cytotoxic bis-aqua ruthenium warhead [Ru(Ph2phen)2(OH2)2]2+, and Ac-MRGDH-NH2 possesses integrin targeting ability and photosubstitution properties. Therefore, Ac-MRGDH-NH2 can be utilized in research on tumor-targeted photodynamic activation chemotherapy (PACT).
    Ac-MRGDH-NH2
  • HY-168087
    GSK3335103
    Inhibitor
    GSK3335103 is an orally active, non-peptide αvβ6 integrin inhibitor (pIC50=8). GSK3335103 can be used in the study of pulmonary fibrosis.
    GSK3335103
  • HY-111348
    Lamifiban
    Antagonist
    Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes.
    Lamifiban
  • HY-P991104
    Anti-EMMPRIN/CD147 Antibody
    Inhibitor
    Anti-EMMPRIN/CD147 Antibody is a human antibody expressed in CHO cells, targeting Basigin. Anti-EMMPRIN/CD147 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-EMMPRIN/CD147 Antibody
  • HY-P990857
    Anti-CD54/ICAM-1 Antibody (R6-5-D6)
    Inhibitor
    Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD54/ICAM-1. The recommend isotype control of Anti-CD54/ICAM-1 Antibody (R6-5-D6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
    Anti-CD54/ICAM-1 Antibody (R6-5-D6)
  • HY-164360
    αVβ8-IN-1
    Inhibitor
    αVβ8-IN-1 is a αVβ8 integrin inhibitor. αVβ8-IN-1 has been shown to inhibit the growth of tumors such as EMT6, CT26, KPC, and TKCC-10. αVβ8-IN-1 can be used in research related to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and tumors.
    αVβ8-IN-1
  • HY-167686
    Variabilin
    Antagonist
    Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg.
    Variabilin
  • HY-120080
    UR-2922
    Antagonist
    UR-2922 is a platelet GPIIb/IIIa antagonist with antiplatelet aggregation and cardiovascular disease inhibition activities. UR-2922 has high affinity for human platelet receptors and has good pharmacokinetic properties, and can be used to inhibit cardiovascular diseases.
    UR-2922
  • HY-116030
    JNJ-26076713
    Antagonist
    JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization.
    JNJ-26076713
  • HY-12290A
    Arg-Gly-Asp-Ser TFA
    Inhibitor
    Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
    Arg-Gly-Asp-Ser TFA
  • HY-P10417
    RTDLDSLRTYTL
    Inhibitor
    RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development.
    RTDLDSLRTYTL
  • HY-10307A
    Roxifiban acetate
    Inhibitor
    Roxifiban (acetate) is the acetate form of Roxifiban (HY-10307). Roxifiban (acetate) is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in research related to angina.
    Roxifiban acetate
  • HY-P1897
    Fibronectin Active Fragment Control
    Ligand
    Fibronectin Active Fragment Control is an active peptide fragment of fibronectin. Fibronectin is a glycoprotein interacting with integrins.
    Fibronectin Active Fragment Control
  • HY-172494A
    DSPE-PEG3400-iRGD
    DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery.
    DSPE-PEG3400-iRGD
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.